Development and Validation of a Prognostic Nomogram for Predicting Overall Survival in Patients with Primary Bladder Sarcoma: a SEER-based Retrospective Study

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2021 Nov 26

PMID 34823525

Citations 2

Authors

Shijie Li

Xuefeng Liu

Xiaonan Chen

Affiliations

Soon will be listed here.

Abstract

Background: Primary bladder sarcoma (PBS) is a rare malignant tumor of the bladder with a poor prognosis, and its disease course is inadequately understood. Therefore, our study aimed to establish a prognostic model to determine individualized prognosis of patients with PBS.

Patients And Methods: Data of 866 patients with PBS, registered from 1973 to 2015, were extracted from the surveillance, epidemiology, and end result (SEER) database. The patients included were randomly split into a training (n = 608) and a validation set (n = 258). Univariate and multivariate Cox regression analyses were employed to identify the important independent prognostic factors. A nomogram was then established to predict overall survival (OS). Using calibration curves, receiver operating characteristic curves, concordance index (C-index), decision curve analysis (DCA), net reclassification improvement (NRI) and integrated discrimination improvement (IDI), the performance of the nomogram was internally validated. We compared the nomogram with the TNM staging system. The application of the risk stratification system was tested using Kaplan-Meier survival analysis.

Results: Age at diagnosis, T-stage, N-stage, M-stage, and tumor size were identified as independent predictors of OS. C-index of the training cohort were 0.675, 0.670, 0.671 for 1-, 3- and 5-year OS, respectively. And that in the validation cohort were 0.701, 0.684, 0.679, respectively. Calibration curves also showed great prediction accuracy. In comparison with TNM staging system, improved net benefits in DCA, evaluated NRI and IDI were obtained. The risk stratification system can significantly distinguish the patients with different survival risk.

Conclusion: A prognostic nomogram was developed and validated in the present study to predict the prognosis of the PBS patients. It may assist clinicians in evaluating the risk factors of patients and formulating an optimal individualized treatment strategy.

Citing Articles

Development and validation of a prognostic nomogram for predicting cancer-specific survival in patients with metastatic clear cell renal carcinoma: A study based on SEER database.

Huang G, Liao J, Cai S, Chen Z, Qin X, Ba L Front Oncol. 2022; 12:949058.

PMID: 36237316 PMC: 9552762. DOI: 10.3389/fonc.2022.949058.

Development and external validation of a dynamic nomogram to predict the survival for adenosquamous carcinoma of the pancreas.

Ren C, Ma Y, Jin J, Ding J, Jiang Y, Wu Y Front Oncol. 2022; 12:927107.

PMID: 36033500 PMC: 9411813. DOI: 10.3389/fonc.2022.927107.

References

Alwan M, Sayed M, Kamal M . Schistosomiasis and sarcoma of the urinary bladder. Eur Urol. 1988; 15(1-2):139-40. DOI: 10.1159/000473414. View

Mills S, FECHNER R, Cantrell R . Aggressive sinonasal lesion resembling normal intestinal mucosa. Am J Surg Pathol. 1982; 6(8):803-9. DOI: 10.1097/00000478-198212000-00012. View

Dali K, Kacem A, Ben Rhouma S, Chaker K, Sellami A, Nouira Y . Carcino-sarcoma of the urinary bladder with cartilaginous differentiation: About a case report. Urol Case Rep. 2019; 28:101053. PMC: 6818139. DOI: 10.1016/j.eucr.2019.101053. View

Malla M, Wang J, Trepeta R, Feng A, Wang J . Sarcomatoid Carcinoma of the Urinary Bladder. Clin Genitourin Cancer. 2016; 14(5):366-372. DOI: 10.1016/j.clgc.2016.03.004. View

Yin K, Luo R, Wei Y, Wang F, Zhang Y, Karlson K . Survival outcomes in patients with primary cardiac sarcoma in the United States. J Thorac Cardiovasc Surg. 2020; 162(1):107-115.e2. DOI: 10.1016/j.jtcvs.2019.12.109. View

Ro J, El-Naggar A, Amin M, Sahin A, Ordonez N, Ayala A . Pseudosarcomatous fibromyxoid tumor of the urinary bladder and prostate: immunohistochemical, ultrastructural, and DNA flow cytometric analyses of nine cases. Hum Pathol. 1993; 24(11):1203-10. DOI: 10.1016/0046-8177(93)90217-5. View

Zhou Z, Wang J, Fang L, Ma J, Guo M . A nomogram for predicting overall survival in patients with Ewing sarcoma: a SEER-based study. BMC Musculoskelet Disord. 2020; 21(1):737. PMC: 7661249. DOI: 10.1186/s12891-020-03706-3. View

Zieschang H, Koch R, Wirth M, Froehner M . Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. Urol Int. 2018; 102(1):96-101. DOI: 10.1159/000494357. View

ALVAREZ ZAMORA R . Bladder sarcoma. Arch Esp Urol. 2010; 3(3):217-26. View

10.

Weiner A, Keeter M, Manjunath A, Meeks J . Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013). Urol Oncol. 2018; 36(5):237.e9-237.e17. DOI: 10.1016/j.urolonc.2017.12.015. View

11.

Robinson S, Farooq A, Laniado M, Motiwala H . The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience. Int Braz J Urol. 2017; 44(1):45-52. PMC: 5815531. DOI: 10.1590/S1677-5538.IBJU.2016.0347. View

12.

Rosser C, Slaton J, Izawa J, Levy L, Dinney C . Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults. Urology. 2003; 61(6):1151-5. DOI: 10.1016/s0090-4295(03)00021-9. View

13.

Guo C, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y . Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019; 27(6):1781-1793.e4. PMC: 6546434. DOI: 10.1016/j.celrep.2019.04.048. View

14.

Ribeiro J, Klojda C, Araujo C, Pires L, Babinski M . Giant Leiomyosarcoma of the Urinary Bladder. J Clin Diagn Res. 2016; 10(5):PD14-5. PMC: 4948478. DOI: 10.7860/JCDR/2016/18971.7858. View

15.

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

16.

Zheng W, Li K, Zhu W, Ding Y, Wu Q, Tang Q . Nomogram prediction of overall survival based on log odds of positive lymph nodes for patients with penile squamous cell carcinoma. Cancer Med. 2020; 9(15):5425-5435. PMC: 7402844. DOI: 10.1002/cam4.3232. View

17.

Navon J, Rahimzadeh M, Wong A, Carpenter P, Ahlering T . Angiosarcoma of the bladder after therapeutic irradiation for prostate cancer. J Urol. 1997; 157(4):1359-60. View

18.

Taylor R, Busuttil A . Case report: adult rhabdomyosarcoma of bladder, complete response to radiation therapy. J Urol. 1989; 142(5):1321-2. DOI: 10.1016/s0022-5347(17)39074-2. View

19.

Ahlering T, Weintraub P, SKINNER D . Management of adult sarcomas of the bladder and prostate. J Urol. 1988; 140(6):1397-9. DOI: 10.1016/s0022-5347(17)42054-4. View

20.

Parekh D, Jung C, OConner J, Dutta S, Smith Jr E . Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology. 2002; 60(1):164. DOI: 10.1016/s0090-4295(02)01701-6. View